Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ann Lee-Karlon | M | - |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | 1 years |
Mitchell Mutz | M | 61 |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | - |
Seiji Miyahara | M | - |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | 1 years |
Samuel Bjork | M | - |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | 1 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Craig Lichtenstein
- Personal Network